The overall goal of this study is to investigate the ability of HER2-targeted therapies to alter oxygenation levels and DNA damage response and enhance the effectiveness of fractionated radiation utilizing noninvasive [18F]-fluoromisonidazole PET imaging to longitudinally monitor tumor response. The gene discussed is ERBB2; the disease is neoplasm.